Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.

[1]  J. Roider,et al.  Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. , 2008, Investigative ophthalmology & visual science.

[2]  R. Soares,et al.  Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects , 2008, Journal of cellular biochemistry.

[3]  R. Apte.  Pegaptanib sodium for the treatment of age-related macular degeneration , 2008 .

[4]  Valerie Quarmby,et al.  Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. , 2007, Experimental eye research.

[5]  R. Soares,et al.  Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells , 2007, Angiogenesis.

[6]  George A. Williams,et al.  TREATMENT OF NAÏVE LESIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB , 2007, Retina.

[7]  K. Bartz-Schmidt,et al.  Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[8]  N. Ferrara,et al.  Antiangiogenesis to treat cancer and intraocular neovascular disorders , 2007, Laboratory Investigation.

[9]  R. Steinbrook,et al.  The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. , 2006, The New England journal of medicine.

[10]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[11]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[12]  L. Damico,et al.  DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[13]  P. Wiedemann,et al.  Antineovascular agents in the treatment of eye diseases. , 2006, Current pharmaceutical design.

[14]  P. Rosenfeld,et al.  Promising new treatments for neovascular age-related macular degeneration , 2006, Expert opinion on investigational drugs.

[15]  Richard F Spaide,et al.  INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[16]  R. Avery,et al.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[17]  Peter K. Kaiser,et al.  ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .

[18]  Philip J Rosenfeld,et al.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[19]  D. Fei,et al.  Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. , 2005, Investigative ophthalmology & visual science.

[20]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[21]  J. Russo,et al.  Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. , 2004, Molecular endocrinology.

[22]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[23]  Emmett T. Cunningham,et al.  VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .

[24]  J. Russo,et al.  17β-Estradiol-Mediated Vessel Assembly and Stabilization in Tumor Angiogenesis Requires TGFβ and EGFR Crosstalk , 2004, Angiogenesis.

[25]  Martin Vanderlaan,et al.  Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro , 2004, Angiogenesis.

[26]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.